touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer.
The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO Annual Meeting.
Citation: J Clin Oncol 39, 2021 (suppl 15; abstr 3584)
1. What is favezelimab (MK4280) and its mechanism of action? (00:14-00:39)
2. What was the rationale for using favezelimab in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer that had progressed on two or more prior therapies? (00:39-01:33)
3. Could you give us an overview of the phase I study and its findings? (01:33-03:08)
4. Which patients had the best response to this combination? (03:08-03:30)
5. What will be the next steps in the clinical development of favezelimab in this treatment setting? (03:30-04:08)
6. What do you think is the most important aspect to consider with regards to immunotherapy in this patient subset? (04:08-04:42)
Disclosures: Research: Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho, BeiGene. Consultant/Advisor: Roche/Genentech, F.Hoffmann/La Roche, Ellipses Pharma, Neomed Therapeutics1 Inc, Boehringer Ingelheim, Janssen Global Services, SeaGen, TFS, Alkermes, Thermo Fisher, Bristol-Mayers Squibb, MabDiscovery, Anaveon. Travel Grants: Bristol-Mayers Squibb, Merck Sharp & Dohme, Menarini, Glycotope. Speakers Bureau: Merck Sharp & Dohme, Roche, Thermo Fisher, Lilly. Clinical Trials PI or Co-PI (Institution): Affimed Gmbh, Amgen SA, Anaveon AG, AstraZeneca AB, Biontech Gmbh, Catalym Gmbh, Cytomx, F.Hoffmann, La Roche Ltd, F-Star Beta Limited, Genentech Inc, Genmab B.V., Hutchison Medipharma Limited, Icon, Imcheck Therapeutics, Immunocore Ltd, Janssen-Cilag SA, Medimmune Llc, Merck Kgga, Novartis Farmacéutica, S.A, Peptomyc, Ribon Therapeutics, Roche Farma SA, Seattle Genetics Inc, Symphogen A/S, Taiho Pharma Usa Inc.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.
Filmed in coverage of the 2021 ASCO Annual Meeting.
Share this Video
Related Videos In Colorectal Cancer
Jared Weiss, ESMO 2021: The Efficacy and Safety Findings of the KRYSTAL-1 Study
touchONCOLOGY joins Dr Jared Weiss (UNC Lineburger Comprehensive Cancer Care Center, Chapel Hill, NC, USA) at ESMO 2021 to discuss KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or Combined with Cetuximab (Cetux) in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation. Questions 1. What is the rationale for targeting KRAS tumour mutations in colorectal cancer? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Hans Prenen, ASCO GI 2021: Updates from the alloSHRINK Study
It was a pleasure to talk to Hans Prenen about recent updates in CAR T cell therapy and the current findings from the alloSHRINK study (Clinical Trial Identifier: NCT03692429). The abstract ‘Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.’ (ABSTRACT NUMBER: 74) was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!